Evidence map›Paper›PMID 30933866›Full record

ArticleNuclear medicine and biology2019

Design, synthesis and evaluation of

John R Lever, Emily A Fergason-Cantrell, Terry L Carmack, Lisa D Watkinson, Fabio Gallazzi

Open access · greenAbstract read
In one paragraph

Article in Nuclear medicine and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Auger electrons for cancer therapy - a review.EJNMMI radiopharmacy and chemistry · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John R LeverDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA; Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA; Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA. Electronic address: leverj@health.missouri.edu.
Emily A Fergason-CantrellDepartment of Radiology, University of Missouri, Columbia, MO 65212, USA; Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
Terry L CarmackRadiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA; Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
Lisa D WatkinsonRadiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA; Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
Fabio GallazziDepartment of Chemistry, University of Missouri, Columbia, MO 65211, USA; Molecular Interaction Core, University of Missouri, Columbia, MO 65211, USA.
Harry S. Truman Memorial Veterans' Hospital · USUniversity of Missouri · US

Funding

Targeting Mu Opioid Receptors in non-Small Cell Lung CancerR21CA174873 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI LEVER, JOHN RILEY · 2013 to 2014
$301k
NCI NIH HHS R21 CA174873
6 · The paper itself

Abstract

introductionPeripheral mu (μ) opioid receptors are implicated in pain, bowel dysfunction and the progression of certain cancers. In an effort to identify radioligands well suited for imaging these peripheral sites, we have prepared and evaluated four hydrophilic

methodsPeptides were prepared by solid-phase techniques, using orthogonal strategies to achieve branching to DOTA, and then characterized by HPLC, mass spectroscopy and amino acid analysis. Scaffolds included novel peptide H-Dmt-D-Ala-Phe-Orn-NH

resultsAll four indium(III)-DOTA conjugates derived from DAPO and [Dmt

conclusionsVisualizing peripheral μ opioid receptors using ADVANCES IN KNOWLEDGE: This study shows in vivo labeling of peripheral μ opioid receptors by a tetrapeptide radioligand, and provides information that should prove useful in the design of peptide radioligands having optimal properties.

Indexed as

Drug DesignIndium RadioisotopesAmino Acid SequenceAnimalsChemistry Techniques, SyntheticHeterocyclic Compounds, 1-RingIsotope LabelingLigandsMaleMiceOligopeptidesProtein BindingReceptors, Opioid, muSubstrate SpecificityTissue Distribution1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidHeterocyclic Compounds, 1-RingIndium-111Indium RadioisotopesLigandsOligopeptidesReceptors, Opioid, muIndium-111Opioid receptorPeptideRadiolabeling

Identifiers

PMID30933866
PMCPMC6591026
OpenAlexW2921275551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.